{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:30:33Z","timestamp":1794274233857,"version":"4.9.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70111980"],"award-info":[{"award-number":["70111980"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1389"],"award-info":[{"award-number":["SFB 1389"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1389"],"award-info":[{"award-number":["SFB 1389"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1389"],"award-info":[{"award-number":["SFB 1389"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["HIPO 2-K25 and 2-K32R"],"award-info":[{"award-number":["HIPO 2-K25 and 2-K32R"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Advances in molecular understanding and diagnostic precision of glioblastoma enable the identification of key genetic alterations in a timely manner and, in principle, allow treatments with targeted compounds based on molecular markers. Here we report the results of the phase 1\/2 umbrella trial NCT Neuro Master Match (N\n                    <jats:sup>2<\/jats:sup>\n                    M\n                    <jats:sup>2<\/jats:sup>\n                    ), which evaluated targeted treatments in 228 patients with newly diagnosed glioblastoma without O6-methylguanine DNA-methyltransferase promoter hypermethylation. Stratification for treatment was conducted by a trial-specific molecular tumor board across five subtrials, each evaluating a targeted therapy\u2014alectinib, idasanutlin, palbociclib, vismodegib or temsirolimus\u2014selected according to the best-matching molecular alteration. Patients without matching alterations were randomized between subtrials without strong biomarkers using atezolizumab and asunercept, and the standard of care (SOC), temozolomide. All received radiotherapy. The primary endpoints were dose-limiting toxicities (phase 1) and progression-free survival at 6 months (PFS-6; phase 2). Secondary endpoints included safety and tolerability, as well as overall survival (OS). The subtrials for alectinib and vismodegib did not open as they did not have matching patients. The idasanutlin subtrial (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20099) was terminated early at the discretion of the manufacturing company. The temsirolimus subtrial (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200946) demonstrated a PFS-6 of 39.1% and median OS of 15.4 months in patients with activated mammalian target of rapamycin (mTOR) signaling compared to a PFS-6 at 18.5% in the SOC group (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200954), meeting the primary endpoint. The atezolizumab (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200942), asunercept (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200926) and palbociclib (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200941) subtrials did not meet the primary endpoint for efficacy. The safety signals of N\n                    <jats:sup>2<\/jats:sup>\n                    M\n                    <jats:sup>2<\/jats:sup>\n                    match prior experiences with the drugs in quality and quantity; no relevant negative interaction with the parallel radiotherapy was noted. The results of the N\n                    <jats:sup>2<\/jats:sup>\n                    M\n                    <jats:sup>2<\/jats:sup>\n                    trial support further investigation of temsirolimus in addition to radiotherapy in patients with newly diagnosed glioblastoma with activated mTOR signaling. ClinicalTrials.gov registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03158389\" ext-link-type=\"uri\">NCT03158389<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-025-03928-9","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T09:04:55Z","timestamp":1757063095000},"page":"3534-3541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1\/2a N2M2 umbrella trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6171-634X","authenticated-orcid":false,"given":"Wolfgang","family":"Wick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa-Marie","family":"Lanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Harting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Dettmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail K.","family":"Suwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Ketter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3542-8782","authenticated-orcid":false,"given":"Ghazaleh","family":"Tabatabai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Seliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Glas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6927-0987","authenticated-orcid":false,"given":"Michael C.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Timmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian A.","family":"Ringel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8825-4908","authenticated-orcid":false,"given":"Iris","family":"Mildenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5886-2322","authenticated-orcid":false,"given":"Walter J.","family":"Schulz-Schaeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4892-6104","authenticated-orcid":false,"given":"Frank","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1915-745X","authenticated-orcid":false,"given":"Christel","family":"Herold-Mende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Eisenmenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5447-5322","authenticated-orcid":false,"given":"Stefan M.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Renovanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bendszus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5441-1962","authenticated-orcid":false,"given":"Felix","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4746-887X","authenticated-orcid":false,"given":"Michael","family":"Platten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8350-7074","authenticated-orcid":false,"given":"Tobias","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"3928_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"3928_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller, M. et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat. Rev. Clin. Oncol. 18, 170\u2013186 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3928_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nrneurol.2014.100","volume":"10","author":"W Wick","year":"2014","unstructured":"Wick, W. et al. MGMT testing\u2014the challenges for biomarker-based glioma treatment. Nat. Rev. Neurol. 10, 372\u2013385 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"3928_CR4","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997\u20131003 (2005).","journal-title":"N. Engl. J. Med."},{"key":"3928_CR5","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-15-3153","volume":"22","author":"W Wick","year":"2016","unstructured":"Wick, W. et al. Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Clin. Cancer Res. 22, 4797\u20134806 (2016).","journal-title":"Clin. Cancer Res."},{"key":"3928_CR6","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.2015.63.4691","volume":"34","author":"U Herrlinger","year":"2016","unstructured":"Herrlinger, U. et al. Bevacizumab plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial. J. Clin. Oncol. 34, 1611\u20131619 (2016).","journal-title":"J. Clin. Oncol."},{"key":"3928_CR7","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/neuonc\/nou356","volume":"17","author":"LB Nabors","year":"2015","unstructured":"Nabors, L. B. et al. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol. 17, 708\u2013717 (2015).","journal-title":"Neuro Oncol."},{"key":"3928_CR8","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1093\/neuonc\/not100","volume":"15","author":"W Wick","year":"2013","unstructured":"Wick, W. et al. Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Neuro Oncol. 15, 1405\u20131412 (2013).","journal-title":"Neuro Oncol."},{"key":"3928_CR9","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/neuonc\/noae108","volume":"26","author":"ME Hegi","year":"2024","unstructured":"Hegi, M. E. et al. No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic\/NOA-08 trials in elderly glioblastoma patients. Neuro Oncol. 26, 1867\u20131875 (2024).","journal-title":"Neuro Oncol."},{"key":"3928_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/neuonc\/noac173","volume":"25","author":"AB Lassman","year":"2023","unstructured":"Lassman, A. B. et al. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. Neuro Oncol. 25, 339\u2013350 (2023).","journal-title":"Neuro Oncol."},{"key":"3928_CR11","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1158\/1078-0432.CCR-15-1015","volume":"22","author":"M Verreault","year":"2016","unstructured":"Verreault, M. et al. Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2-amplified and TP53 wild-type glioblastomas. Clin. Cancer Res. 22, 1185\u20131196 (2016).","journal-title":"Clin. Cancer Res."},{"key":"3928_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s11060-018-2977-3","volume":"140","author":"JW Taylor","year":"2018","unstructured":"Taylor, J. W. et al. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. J. Neurooncol. 140, 477\u2013483 (2018).","journal-title":"J. Neurooncol."},{"key":"3928_CR13","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-23-3241","volume":"30","author":"KC Schreck","year":"2024","unstructured":"Schreck, K. C. et al. Response rate and molecular correlates to encorafenib and binimetinib in BRAF-V600E mutant high-grade glioma. Clin. Cancer Res. 30, 2048\u20132056 (2024).","journal-title":"Clin. Cancer Res."},{"key":"3928_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11060-019-03348-z","volume":"146","author":"A Berberich","year":"2020","unstructured":"Berberich, A. et al. cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma. J. Neurooncol. 146, 9\u201323 (2020).","journal-title":"J. Neurooncol."},{"key":"3928_CR15","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1200\/JCO.2014.60.1591","volume":"33","author":"GW Robinson","year":"2015","unstructured":"Robinson, G. W. et al. Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032. J. Clin. Oncol. 33, 2646\u20132654 (2015).","journal-title":"J. Clin. Oncol."},{"key":"3928_CR16","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/neuonc\/noaa033","volume":"22","author":"A Wick","year":"2020","unstructured":"Wick, A. et al. Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. Neuro Oncol. 22, 1162\u20131172 (2020).","journal-title":"Neuro Oncol."},{"key":"3928_CR17","doi-asserted-by":"publisher","first-page":"55319","DOI":"10.18632\/oncotarget.19429","volume":"8","author":"M Li","year":"2017","unstructured":"Li, M. et al. CDK4\/6 inhibition is more active against the glioblastoma proneural subtype. Oncotarget 8, 55319\u201355331 (2017).","journal-title":"Oncotarget"},{"key":"3928_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/neuonc\/noy161","volume":"21","author":"W Wick","year":"2019","unstructured":"Wick, W. et al. N2M2 (NOA-20) phase I\/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro Oncol. 21, 95\u2013105 (2019).","journal-title":"Neuro Oncol."},{"key":"3928_CR19","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/neuonc\/noad100","volume":"25","author":"F Sahm","year":"2023","unstructured":"Sahm, F. et al. Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline. Neuro Oncol. 25, 1731\u20131749 (2023).","journal-title":"Neuro Oncol."},{"key":"3928_CR20","doi-asserted-by":"publisher","first-page":"6304","DOI":"10.1158\/1078-0432.CCR-14-0951-T","volume":"20","author":"W Wick","year":"2014","unstructured":"Wick, W. et al. A phase II, randomized, study of weekly APG101\u2009+\u2009reirradiation versus reirradiation in progressive glioblastoma. Clin. Cancer Res. 20, 6304\u20136313 (2014).","journal-title":"Clin. Cancer Res."},{"key":"3928_CR21","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1158\/1078-0432.CCR-23-0926","volume":"29","author":"T Kessler","year":"2023","unstructured":"Kessler, T. et al. Prognostic markers of DNA methylation and next-generation sequencing in progressive glioblastoma from the EORTC-26101 trial. Clin. Cancer Res. 29, 3892\u20133900 (2023).","journal-title":"Clin. Cancer Res."},{"key":"3928_CR22","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S1470-2045(14)70489-9","volume":"15","author":"DN Franz","year":"2014","unstructured":"Franz, D. N. et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol. 15, 1513\u20131520 (2014).","journal-title":"Lancet Oncol."},{"key":"3928_CR23","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess, G. et al. Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 27, 3822\u20133829 (2009).","journal-title":"J. Clin. Oncol."},{"key":"3928_CR24","volume":"2","author":"T Kessler","year":"2020","unstructured":"Kessler, T. et al. Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma. Neurooncol. Adv. 2, vdz060 (2020).","journal-title":"Neurooncol. Adv."},{"key":"3928_CR25","doi-asserted-by":"publisher","first-page":"693104","DOI":"10.3389\/fonc.2021.693104","volume":"11","author":"MA George","year":"2021","unstructured":"George, M. A., Qureshi, S., Omene, C., Toppmeyer, D. L. & Ganesan, S. Clinical and pharmacologic differences of CDK4\/6 inhibitors in breast cancer. Front. Oncol. 11, 693104 (2021).","journal-title":"Front. Oncol."},{"key":"3928_CR26","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1158\/1078-0432.CCR-21-3521","volume":"29","author":"AF Blandin","year":"2023","unstructured":"Blandin, A. F. et al. ALK amplification and rearrangements are recurrent targetable events in congenital and adult glioblastoma. Clin. Cancer Res. 29, 2651\u20132667 (2023).","journal-title":"Clin. Cancer Res."},{"key":"3928_CR27","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1038\/nm.3328","volume":"19","author":"MG Filbin","year":"2013","unstructured":"Filbin, M. G. et al. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat. Med. 19, 1518\u20131523 (2013).","journal-title":"Nat. Med."},{"key":"3928_CR28","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/neuonc\/not236","volume":"16","author":"K Han","year":"2014","unstructured":"Han, K. et al. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncol. 16, 696\u2013706 (2014).","journal-title":"Neuro Oncol."},{"key":"3928_CR29","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","volume":"18","author":"Adaptive Platform Trials Coalition","year":"2019","unstructured":"Adaptive Platform Trials Coalition Adaptive platform trials: definition, design, conduct and reporting considerations. Nat. Rev. Drug Discov. 18, 797\u2013807 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3928_CR30","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/neuonc\/nox216","volume":"20","author":"E Pfaff","year":"2018","unstructured":"Pfaff, E. et al. Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation\u2014the NCT Neuro Master Match (N2M2) pilot study. Neuro Oncol. 20, 826\u2013837 (2018).","journal-title":"Neuro Oncol."},{"key":"3928_CR31","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","volume":"555","author":"D Capper","year":"2018","unstructured":"Capper, D. et al. DNA methylation-based classification of central nervous system tumours. Nature 555, 469\u2013474 (2018).","journal-title":"Nature"},{"key":"3928_CR32","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00401-015-1519-8","volume":"131","author":"F Sahm","year":"2016","unstructured":"Sahm, F. et al. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 131, 903\u2013910 (2016).","journal-title":"Acta Neuropathol."},{"key":"3928_CR33","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/ng.3036","volume":"46","author":"A Rimmer","year":"2014","unstructured":"Rimmer, A. et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat. Genet. 46, 912\u2013918 (2014).","journal-title":"Nat. Genet."},{"key":"3928_CR34","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 28, 1963\u20131972 (2010).","journal-title":"J. Clin. Oncol."},{"key":"3928_CR35","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","volume":"16","author":"H Okada","year":"2015","unstructured":"Okada, H. et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 16, e534\u2013e542 (2015).","journal-title":"Lancet Oncol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03928-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03928-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03928-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T14:04:33Z","timestamp":1760623473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03928-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3928"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03928-9","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"assertion":[{"value":"8 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.W. declares consulting fees from Enterome, GSK and Servier. He received trial support with drugs from Apogenix, Pfizer and Roche. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}